PART I - Financial Information [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) The company presents unaudited Q1 2025 financials showing a $7.3 million net loss and an accumulated deficit of $48.0 million, raising going concern doubts Condensed Balance Sheet Data (Unaudited) | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $35,530,624 | $38,339,762 | | Total current assets | $38,373,248 | $44,308,428 | | Total assets | $38,404,996 | $44,347,016 | | Total current liabilities | $4,341,004 | $3,824,474 | | Total liabilities | $5,035,439 | $4,769,921 | | Accumulated deficit | $(48,043,927) | $(40,737,170) | | Total stockholders' equity | $33,369,557 | $39,577,095 | Condensed Statements of Operations (Unaudited) | Metric | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Collaboration revenue | $257,884 | $126,838 | | Research and development expenses | $5,214,076 | $3,138,159 | | General and administrative expenses | $2,713,890 | $2,439,841 | | Loss from operations | $(7,676,922) | $(5,483,002) | | Net loss | $(7,306,757) | $(5,051,913) | | Net loss per share, basic and diluted | $(0.44) | $(0.35) | Condensed Statements of Cash Flows (Unaudited) | Cash Flow Activity | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Net cash (used in) provided by operating activities | $(2,828,275) | $2,145,874 | | Net cash used in investing activities | $0 | $(25,000) | | Net cash provided by financing activities | $19,137 | $1,241,764 | | Net (decrease) increase in cash | $(2,809,138) | $3,362,638 | - The company has incurred losses since inception, with an **accumulated deficit of $48.0 million** as of March 31, 2025; management expects its **$35.5 million in cash** to fund operations for at least one year but requires substantial future financing[18](index=18&type=chunk)[19](index=19&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=25&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses a Q1 2025 net loss of $7.3 million, driven by a $2.1 million increase in R&D expenses, and confirms sufficient cash for the next year [Overview](index=26&type=section&id=Overview) The company is a clinical-stage biotech focused on Treg therapies, reporting a Q1 2025 net loss of $7.3 million and an accumulated deficit of $48.0 million - The company's core focus is on developing proprietary therapies to enhance the function of regulatory T cells (Tregs) to address dysfunction in neurodegenerative, autoimmune, and metabolic diseases[90](index=90&type=chunk)[91](index=91&type=chunk) - The lead asset, **COYA 302**, is a combination of proprietary low-dose interleukin-2 and CTLA4-Ig, considered a 'Pipeline in a Product' due to its potential across multiple indications[93](index=93&type=chunk) - The company incurred a **net loss of $7.3 million** in Q1 2025 and had an **accumulated deficit of $48.0 million** as of March 31, 2025[93](index=93&type=chunk) [Recent Developments](index=28&type=section&id=Recent%20Developments) The company expanded its pipeline with COYA 303 in January 2025 and published positive preclinical results in April showing enhanced Treg function - On January 21, 2025, the company expanded its pipeline with a new product candidate, **COYA 303**, a combination of COYA 301 and a GLP-1 receptor agonist for inflammatory diseases[97](index=97&type=chunk) - A preclinical study published on April 21, 2025, showed that COYA 303 produced a statistically significant **increase in Treg suppressive function of 42%** (p < 0.001) and promoted Treg survival[98](index=98&type=chunk)[100](index=100&type=chunk) [Results of Operations](index=32&type=section&id=Results%20of%20Operations) The Q1 2025 net loss widened to $7.3 million from $5.1 million year-over-year, driven by a $2.1 million increase in R&D expenses for COYA 302 Comparison of Operations for the Three Months Ended March 31 | Metric | 2025 | 2024 | Change | | :--- | :--- | :--- | :--- | | Collaboration revenue | $257,884 | $126,838 | $131,046 | | Research and development | $5,214,076 | $3,138,159 | $2,075,917 | | General and administrative | $2,713,890 | $2,439,841 | $274,049 | | Loss from operations | $(7,676,922) | $(5,483,002) | $(2,193,920) | | Net loss | $(7,306,757) | $(5,051,913) | $(2,254,844) | - **R&D expenses increased by $2.1 million**, primarily due to a **$1.5 million increase** in preclinical expenses for the advancement of COYA 302 in ALS[116](index=116&type=chunk) - **G&A expenses increased by $0.3 million**, mainly due to a **$0.4 million increase** in stock-based compensation, partially offset by a $0.2 million decrease in board fees and taxes[118](index=118&type=chunk) [Liquidity and Capital Resources](index=34&type=section&id=Liquidity%20and%20Capital%20Resources) The company holds $35.5 million in cash, sufficient for at least one year, but will require significant additional capital for future clinical trials - As of March 31, 2025, the company had **$35.5 million in cash** and cash equivalents and an **accumulated deficit of $48.0 million**, with cash expected to fund operations for at least one year[120](index=120&type=chunk) Summary of Cash Flows | Cash Flow Activity | Three Months Ended March 31, 2025 | Three Months Ended March 31, 2024 | | :--- | :--- | :--- | | Cash (used in) provided by operating activities | $(2,828,275) | $2,145,874 | | Cash provided by financing activities | $19,137 | $1,241,764 | - The DRL Development Agreement provides for potential future milestone payments, including **$4.2 million upon FDA acceptance of an IND** for COYA 302 and another **$4.2 million upon dosing of the first patient** in a Phase 2 trial[136](index=136&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=40&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a smaller reporting company, this section is not applicable, indicating no significant market risk exposure requiring disclosure - The company states this section is **'Not applicable'**[149](index=149&type=chunk) [Controls and Procedures](index=41&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of March 31, 2025, with no material changes to internal controls - Based on an evaluation as of March 31, 2025, management concluded that the company's disclosure controls and procedures were **effective** at the reasonable assurance level[150](index=150&type=chunk) - There were **no material changes** in internal control over financial reporting during the quarter that are reasonably likely to materially affect the company's internal controls[151](index=151&type=chunk) PART II - Other Information [Legal Proceedings](index=42&type=section&id=Item%201.%20Legal%20Proceedings) The company reports it is not currently involved in any legal proceedings - The company reports **'None'** for legal proceedings[154](index=154&type=chunk) [Risk Factors](index=42&type=section&id=Item%201A.%20Risk%20Factors) The company confirms no material changes to the risk factors previously disclosed in its 2024 Annual Report on Form 10-K - There have been **no material changes** from the risk factors disclosed in the Annual Report on Form 10-K for the year ended December 31, 2024[155](index=155&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=42&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities during the period - The company reports **'None'** for unregistered sales of equity securities[156](index=156&type=chunk) [Other Information](index=42&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted or terminated a Rule 10b5-1 trading arrangement during the first quarter of 2025 - During the quarter ended March 31, 2025, **none of the company's directors or officers adopted or terminated a Rule 10b5-1 trading arrangement**[159](index=159&type=chunk) [Exhibits](index=42&type=section&id=Item%206.%20Exhibits) This section lists filed exhibits, including required officer certifications and Inline XBRL documents - The report includes required certifications from the CEO and CFO (Exhibits 31.1, 31.2, 32.1) and **Inline XBRL data files**[160](index=160&type=chunk)

Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update Houston, TX, May 13, 2025 -- Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2025. Recent Corporate Highlights Upcoming Expected Catalysts for 2025 • Announced positive interim results of an in ...

Core Insights - Sibylla Biotech has appointed Dieter Weinand as Chairman of its Board of Directors, bringing over 35 years of experience in the pharmaceutical sector [1][4] - The company aims to advance its innovative PPI-FIT technology and pipeline of folding interference small molecules to address challenging therapeutic areas [1][3] Company Overview - Sibylla Biotech is focused on transforming drug discovery by targeting protein folding intermediates, which represents a new druggable dimension in pharmacology [6] - The proprietary PPI-FIT technology allows the company to predict and target intermediate steps in the protein folding process, leading to targeted protein degradation [6][7] Leadership Background - Dieter Weinand has a distinguished career, having held significant roles at major pharmaceutical companies such as Bayer Pharmaceuticals AG, Sanofi, Bristol-Meyers Squibb, and Pfizer [4][5] - His leadership experience includes overseeing the integration of R&D, manufacturing, and commercial functions, contributing to the launch of several high-impact medicines [4] Strategic Vision - The appointment of Mr. Weinand is seen as a strategic move to unlock access to previously undruggable targets and drive the next stages of Sibylla's growth [2][3] - The company is building a pipeline of treatments for high medical need diseases across multiple therapeutic areas, with a mission to bring protein folding interference therapeutics to patients [7]

Company Overview - Coya Therapeutics, Inc. (COYA) is a stock within the Medical sector, which comprises 1000 individual stocks and holds a Zacks Sector Rank of 2, indicating strong performance relative to other sectors [2][3]. Performance Analysis - Coya Therapeutics has shown a year-to-date return of approximately 7.7%, outperforming the Medical sector's average return of -2.9% [4]. - The Zacks Consensus Estimate for COYA's full-year earnings has increased by 7.8% over the past quarter, reflecting improved analyst sentiment and a stronger earnings outlook [4]. Industry Context - Coya Therapeutics is part of the Medical - Biomedical and Genetics industry, which includes 508 stocks and currently ranks 76 in the Zacks Industry Rank. This industry has experienced an average loss of 4% year-to-date, indicating that COYA is performing better than its peers [6]. - In comparison, another stock in the Medical sector, Doximity (DOCS), has a year-to-date return of 6.2% and a Zacks Rank of 2, with a consensus EPS estimate increase of 13.2% over the past three months [5][6].

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Core Viewpoint - Coya Therapeutics, Inc. (COYA) shows significant upside potential with a mean price target of $16.25, indicating a 144.7% increase from its current price of $6.64 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $2.06, suggesting variability among analysts; the lowest estimate of $14 indicates an 110.8% increase, while the highest target is $18, representing a 171.1% increase [2] - A low standard deviation in price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction and magnitude [9] Earnings Estimates and Analyst Consensus - Analysts have shown increasing optimism about COYA's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, one estimate has increased, leading to a 7.8% rise in the Zacks Consensus Estimate for the current year [12] - COYA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]

Core Viewpoint - Coya Therapeutics, Inc. (COYA) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][4]. Earnings Estimates and Revisions - The Zacks rating system is based on the changing earnings picture of a company, specifically tracking the Zacks Consensus Estimate for EPS from sell-side analysts [2]. - Coya Therapeutics is projected to earn -$1.36 per share for the fiscal year ending December 2025, reflecting a year-over-year decline of 38.8% [9]. - Over the past three months, the Zacks Consensus Estimate for Coya has increased by 7.8%, indicating a positive trend in earnings estimates [9]. Impact of Institutional Investors - Changes in a company's future earnings potential, as shown through earnings estimate revisions, are strongly correlated with near-term stock price movements, influenced by institutional investors who adjust their valuations based on these estimates [5][6]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [8]. - Coya Therapeutics' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, suggesting a strong potential for market-beating returns in the near term [11].

Core Viewpoint - Coya Therapeutics, Inc. (COYA) shows significant upside potential with a mean price target of $16.25, indicating a 149.6% increase from its current price of $6.51 [1] Price Targets and Analyst Estimates - The mean estimate consists of four short-term price targets with a standard deviation of $2.06, where the lowest estimate of $14 suggests an 115.1% increase, and the highest estimate of $18 indicates a 176.5% increase [2] - A low standard deviation among price targets suggests strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Analyst Sentiment - Analysts have shown growing optimism regarding COYA's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with potential stock price movements [11] - The Zacks Consensus Estimate for the current year has increased by 7.8% over the past month, with one estimate rising and no negative revisions [12] Zacks Rank and Investment Potential - COYA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13]

Financial Performance - Coya Therapeutics reported net losses of $14.9 million and $8.0 million for the years ended December 31, 2024 and 2023, respectively, with an accumulated deficit of $40.7 million as of December 31, 2024[20]. - Significant expenses and operating losses are anticipated as the company advances its product candidates through development and clinical trials, with a focus on securing additional capital for operations[21][23]. - Coya Therapeutics' financial statements are prepared on a going-concern basis, indicating potential challenges in securing adequate financing for ongoing operations[23]. - The pharmaceutical industry is highly competitive, with many companies having greater financial flexibility and resources, which may impact the company's ability to pursue certain strategies[108]. Product Development and Pipeline - The company is advancing its lead asset, COYA 302, a Treg-enhancing biologic, which has completed Phase 1 and Phase 2a studies in amyotrophic lateral sclerosis (ALS) and is expected to file an IND for a Phase 2 trial in ALS in Q2 2025[19][27]. - Coya Therapeutics announced the expansion of its pipeline with COYA 303, targeting inflammatory diseases, which demonstrated a dual immunomodulatory mechanism of action in preclinical studies[24]. - The company plans to expand COYA 302's indications beyond ALS to include frontotemporal dementia (FTD) and Parkinson's disease (PD), with clinical data for FTD expected in the second half of 2025[25][28]. - COYA 302 is described as a "Pipeline in a Product," indicating its potential to address multiple neurodegenerative conditions through a combination of therapies[20]. - The company is expanding the COYA 302 pipeline to include FTD, PD, and AD, with plans to file INDs for these conditions following ALS[56]. - COYA 303, a combination of COYA 301 and a GLP-1 receptor agonist, is being developed for inflammatory diseases, with preclinical studies showing additive/synergistic anti-inflammatory effects[86]. Clinical Trials and Results - A proof-of-concept study in ALS patients showed no decline or minimal decline in ALSFRS-R scores at 24 weeks (33.75 ±3.3) and 48 weeks (32 ±7.8) compared to baseline (33.5 ±5.9), indicating clinically meaningful disease progression amelioration[49]. - Treg suppressive function increased significantly during treatment, with percentages of inhibition rising from 62.1±8.1 at baseline to 79.9±9.6 at 24 weeks and 89.5±4.1 at 48 weeks (p<0.01)[51]. - The POC study indicated enhanced Treg function and well-tolerated treatment with no serious adverse events reported over 48 weeks[54]. - COYA 301 demonstrated significant enhancement in Treg function and a clinically meaningful 4.93-point improvement in ADAS-Cog14 score compared to placebo[69]. - The Phase 2 trial showed that LD IL-2 q4wks treatment significantly improved CSF Aβ42 levels (p = 0.045) compared to placebo, indicating a potential mechanism for cognitive benefit[78]. - The study indicated a 27% slower decline in CDR-SOB scores following LD IL-2 q4wks treatment compared to placebo[77]. - Statistically significant reductions in pro-inflammatory markers CCL2 (p < 0.05) and IL-15 (p < 0.001) were observed in patients receiving monthly LD IL-2 cycles[83]. Regulatory and Compliance - Regulatory approvals for biologics require substantial time and financial resources, and failure to comply with regulations may lead to significant sanctions[115]. - The FDA requires extensive preclinical studies and clinical trials before a product candidate can be marketed in the U.S., including compliance with good laboratory practice (GLP) and good clinical practice (GCP) regulations[116]. - An Investigational New Drug (IND) application must be submitted to the FDA, which becomes effective 30 days after receipt unless concerns are raised[117]. - The FDA may require a Risk Evaluation and Mitigation Strategy (REMS) to ensure that the benefits of the drug outweigh its risks, which can affect marketability[128]. - Companies must submit annual progress reports on clinical trials to the FDA, including safety reports for serious adverse events[122]. - The FDA may inspect manufacturing facilities and clinical trial sites to ensure compliance with regulations before approving a BLA[130]. - The FDA requires post-market testing and surveillance to monitor product safety and effectiveness after commercialization[145]. Intellectual Property and Agreements - The company has filed several patent applications to protect COYA 303, which combines COYA 301 and a glucagon-like-peptide-1 receptor agonist[24]. - The company has a patent estate that includes one U.S. non-provisional patent application and six foreign patent applications, expected to expire between 2040 and 2044, depending on potential extensions[194][196][198]. - The company has entered into a Development and License Agreement with Dr. Reddy's Laboratories, granting exclusive rights to commercialize COYA 302 for ALS in the U.S., Canada, EU, and UK, with a one-time payment of $3.9 million received[200]. - The company is entitled to receive up to approximately $40.0 million in development milestones and approximately $677.3 million in sales milestones related to COYA 302, contingent on achieving specified milestones[203]. - The company has a License and Supply Agreement with Dr. Reddy's for the development of COYA 302, which includes a non-refundable upfront fee of $0.4 million and potential milestone payments totaling approximately $20.0 million[207]. Challenges and Risks - The company may face challenges in obtaining or maintaining required licenses or permits due to complex and frequently changing environmental regulations[182]. - The company is subject to stringent requirements under the GDPR, which includes special protections for sensitive health information and the right for individuals to seek legal remedies[179]. - The company may need to implement additional mechanisms to ensure compliance with new data protection rules due to the GDPR[180]. - The company faces increased scrutiny from federal and state enforcement bodies regarding interactions with healthcare providers, leading to potential investigations and reputational harm[168]. - The company must comply with various federal and state regulations regarding data privacy and security, including HIPAA and GDPR, which impose strict requirements and potential fines of up to 4% of global revenues or €20,000,000 for non-compliance[165][179].

Financial Performance - Coya Therapeutics reported a net loss of $14.9 million for the year ended December 31, 2024, compared to a net loss of $8.0 million for the year ended December 31, 2023, representing an increase of 86.25%[13] - Net loss for 2024 was $14,880,787, compared to a net loss of $7,987,836 in 2023, reflecting an increase in losses of approximately 86%[26] - Net loss per share increased to $0.98 in 2024 from $0.79 in 2023, indicating a deterioration in per-share performance[26] - The company reported a pre-tax loss of $15,601,074 in 2024, compared to a pre-tax loss of $7,263,984 in 2023, indicating a worsening of about 115%[26] Expenses - Research and development (R&D) expenses increased to $11.9 million in FY 2024 from $5.5 million in FY 2023, primarily due to a $5.0 million rise in preclinical expenses[11] - General and administrative expenses rose to $8.9 million in FY 2024 from $7.8 million in FY 2023, an increase of approximately 14.1%[12] - Total operating expenses increased to $20,803,772 in 2024, up from $13,905,555 in 2023, marking an increase of about 50%[26] - Stock-based compensation increased significantly to $2,663,539 in 2024 from $872,248 in 2023, representing an increase of approximately 205%[28] Cash Flow and Assets - Cash and cash equivalents as of December 31, 2024, were $38.3 million, up from $32.6 million as of December 31, 2023, indicating a growth of 17.5%[10] - Cash and cash equivalents at the end of 2024 were $38,339,762, up from $32,626,768 at the end of 2023, showing an increase of about 17%[28] - The company had a net cash provided by financing activities of $16,026,816 in 2024, down from $38,425,063 in 2023, a decrease of approximately 58%[28] - Coya's total assets increased to $44.3 million as of December 31, 2024, compared to $41.3 million as of December 31, 2023[24] Revenue and Collaboration - Collaboration revenue decreased to $3,554,061 in 2024 from $6,002,206 in 2023, representing a decline of approximately 41%[26] - The company recorded a collaboration receivable of $7,500,000 in 2024, compared to a negative $7,500,000 in 2023, indicating a significant change in cash flow dynamics[28] Strategic Initiatives - Coya raised $10.0 million in a private placement of 1.38 million shares of common stock, primarily from existing institutional shareholders[4] - The company received a strategic investment of $5.0 million from the Alzheimer's Drug Discovery Foundation to support the development of COYA 302 for Frontotemporal Dementia[4] - Coya is on track to initiate a randomized, double-blind controlled Phase 2b trial in patients with Amyotrophic Lateral Sclerosis (ALS) upon IND acceptance[6] - The company plans to submit additional nonclinical data to support the start of the COYA-302 Phase 2 trial in ALS in Q2 2025[9] - The company is expected to publish ALS biomarker data and additional clinical data in the second half of 2025, which may provide insights into the role of inflammation in neurodegenerative diseases[9]